Published in J Virol on December 01, 2000
The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol (2005) 2.35
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain. J Virol (2003) 1.10
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J Virol (2010) 1.01
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00
A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses. J Virol (2007) 0.89
Reduced genetic diversity in lymphoid and central nervous system tissues and selection-induced tissue-specific compartmentalization of neuropathogenic SIVsmmFGb during acute infection. AIDS Res Hum Retroviruses (2009) 0.85
SIVsm quasispecies adaptation to a new simian host. PLoS Pathog (2005) 0.82
Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system. AIDS Res Hum Retroviruses (2010) 0.81
Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J Virol (2012) 0.79
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science (1990) 8.07
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol (1997) 5.18
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol (1991) 3.46
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol (1997) 3.33
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol (1997) 2.04
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.87
Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses (1992) 1.60
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine (1994) 1.31
Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1992) 1.19
Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV). J Immunol Methods (1986) 1.11
Macaque models for AIDS vaccine development. Curr Opin Immunol (1996) 1.10
HIV-1 neutralizing antibodies: how full is the bottle? Nat Med (1999) 1.09
Sequence variation in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1 region. J Gen Virol (1993) 1.07
Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. J Virol (1997) 0.99
The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology (1996) 0.92
Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Virology (1996) 0.89
Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251. AIDS Res Hum Retroviruses (1995) 0.86
Specificity and neutralizing capacity of three monoclonal antibodies produced against the envelope glycoprotein of simian immunodeficiency virus isolate 251. Virology (1995) 0.85
Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.82
A subunit vaccine consisting of gp130 oligomers but not of gp130 monomers protects rhesus macaques against productive infection with SIVmac32H. AIDS (1998) 0.80
Improvement of PCR amplified DNA sequencing with the aid of detergents. Nucleic Acids Res (1990) 5.13
Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature (1988) 3.63
Nucleotide sequence of the envelope gene of Friend murine leukemia virus. J Virol (1983) 3.41
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18
Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol (1986) 2.65
Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem (1988) 2.48
Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science (1999) 2.21
Properties of mouse leukemia viruses. VII. The major viral glycoprotein of friend leukemia virus. Isolation and physicochemical properties. Virology (1974) 2.09
Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals. EMBO J (1986) 2.01
Properties of mouse leukemia viruses. VIII. The major viral glycoprotein of Friend leukemia virus. Seroimmunological, interfering and hemagglutinating capacities. Virology (1974) 1.98
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis (1997) 1.79
[Production of substantial amounts of Friend leukemia virus by a suspension tissue culture line (Eveline suspension cells) (author's transl)]. Z Naturforsch C (1976) 1.69
Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1995) 1.69
Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med (1996) 1.68
Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. Virology (1975) 1.63
Molecular breeding of viruses. Nat Genet (2000) 1.63
Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. Virology (1973) 1.59
Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology (1995) 1.55
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
Metabolic disorder as early consequence of simian immunodeficiency virus infection in rhesus macaques. Lancet (1991) 1.48
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Association of simian immunodeficiency virus Nef with cellular serine/threonine kinases is dispensable for the development of AIDS in rhesus macaques. Nat Med (1997) 1.48
Properties of mouse leukemia viruses. X. Occurrence of viral structural antigens on the cell surface as revealed by a cytotoxicity test. Virology (1976) 1.47
Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology (1981) 1.43
C-type particles produced by a permanent cell line from a leukemic pig. I. Origin and properties of the host cells and some evidence for the occurrence of C-type-like particles. Virology (1974) 1.38
Properties of mouse leukemia viruses. IX. Active and passive immunization of mice against Friend leukemia with isolated viral GP71 glycoprotein and its corresponding antiserum. Virology (1975) 1.37
Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol (2001) 1.35
Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses (1987) 1.29
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol (1996) 1.27
Properties of mouse leukemia viruses. XI. Immunoelectron microscopic studies on viral structural antigens on the cell surface. Virology (1976) 1.25
Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun (2007) 1.22
Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res Hum Retroviruses (1994) 1.20
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Seroepidemiology of human immunodeficiency virus in Africa. Br Med J (Clin Res Ed) (1986) 1.20
Prion disease associated with a novel nine octapeptide repeat insertion in the PRNP gene. Brain Res Mol Brain Res (1995) 1.20
Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction. J Infect Dis (1994) 1.19
Simian lentiviruses--the SIV group. AIDS (1988) 1.14
Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis (2000) 1.13
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. Virology (2001) 1.12
Differences in HERV-K LTR insertions in orthologous loci of humans and great apes. Gene (2000) 1.12
Generation of macaque B lymphoblastoid cell lines with simian Epstein-Barr-like viruses: transformation procedure, characterization of the cell lines and occurrence of simian foamy virus. J Virol Methods (1992) 1.10
Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection. Virology (1992) 1.09
Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS (1990) 1.07
Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. AIDS (1994) 1.06
HTLV positivity in Africans. Lancet (1985) 1.06
Rosettes from Friend leukemia virus envelope: preparation and physicochemical and partial biological characterization. J Virol (1979) 1.06
HTLV-III antibody frequency and severity of lymphadenopathy. Lancet (1984) 1.04
Envelope polypeptides of Friend leukemia virus: purification and structural analysis. J Virol (1980) 1.03
Sera from adult T-cell leukemia patients react with envelope and core polypeptides of adult T-cell leukemia virus. Virology (1984) 1.02
Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS (1993) 1.02
Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet (2007) 1.01
Glycoproteins of friend murine leukemia virus: separation and NH2-terminal amino acid sequences of gp69 and gp71. J Virol (1982) 1.01
Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma. Med Microbiol Immunol (1983) 1.00
Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. J Virol (1997) 0.99
C-type particles produced by a permanent cell line from a leukemic pig. II. Physical, chemical, and serological characterization of the particles. Virology (1974) 0.99
Induction of antibodies against human prion proteins (PrP) by DNA-mediated immunization of PrP0/0 mice. J Immunol Methods (1996) 0.99
Properties of mouse leukemia viruses. IV. Hemagglutination assay and characterization of hemagglutinating surface components. Virology (1973) 0.99
Surface expression of murine leukemia virus structural polypeptides on host cells and the virion. Int J Cancer (1978) 0.98
Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques. J Virol (1998) 0.98
Molecular cloning and characterization of a German HIV-1 isolate. AIDS Res Hum Retroviruses (1990) 0.97
The effect of simian immunodeficiency virus infection in vitro and in vivo on the cytokine production of isolated microglia and peripheral macrophages from rhesus monkey. Virology (1996) 0.97
Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta. Virology (1997) 0.96
Adult T-cell leukemia-associated antigen (ATLA): detection of a glycoprotein in cell- and virus-free supernatant. Z Naturforsch C (1982) 0.96
A rare event of insertion polymorphism of a HERV-K LTR in the human genome. Genomics (2004) 0.96
Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J Med Primatol (2001) 0.96
Expression and frameshifting but extremely inefficient proteolytic processing of the HIV-1 gag and pol gene products in stably transfected rodent cell lines. Virology (1991) 0.95
Sequence analysis of Gardner-Arnstein feline leukaemia virus envelope gene reveals common structural properties of mammalian retroviral envelope genes. EMBO J (1983) 0.95
An anti-CD4 antibody for treatment of chronic inflammatory arthritis. Agents Actions Suppl (1991) 0.95
Experimental infection of rhesus monkeys with SIV isolated from African green monkeys. Intervirology (1989) 0.95
Properties of mouse leukemia viruses. VI. The core of Friend virus; isolation and constituents. Virology (1973) 0.95
Major oligosaccharides in the glycoprotein of Friend murine leukemia virus: structure elucidation by one- and two-dimensional proton nuclear magnetic resonance and methylation analysis. Biochemistry (1984) 0.95
Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs. AIDS Res Hum Retroviruses (1988) 0.94
A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology (1990) 0.92
Specific determination of the proteinase K-resistant form of the prion protein using two-site immunometric assays. Application to the post-mortem diagnosis of BSE. Arch Virol Suppl (2000) 0.92
Urinary neopterin concentrations in rhesus monkeys after infection with simian immunodeficiency virus (SIVmac 251). AIDS (1989) 0.92
Alterations of thymus cortical epithelium and interdigitating dendritic cells but no increase of thymocyte cell death in the early course of simian immunodeficiency virus infection. Am J Pathol (1993) 0.92
Expression of HTLV-specific polypeptides in various human T-cell lines. Med Microbiol Immunol (1984) 0.92
Inactivation of simian immunodeficiency virus by hydrostatic pressure. Proc Natl Acad Sci U S A (1995) 0.92
Mitochondrial 16S rRNA gene encodes a functional peptide, a potential drug for Alzheimer's disease and target for cancer therapy. Med Hypotheses (2002) 0.91
Adult T-cell leukemia (ATL) virus-specific antibodies in ATL patients and healthy virus carriers. Int J Cancer (1983) 0.91
Detection of serum antibodies to adult T-cell leukemia virus in non-human primates and in people from Africa. Int J Cancer (1983) 0.91
Possible cell surface receptor for Friend murine leukemia virus isolated with viral envelope glycoprotein complexes. J Virol (1980) 0.91
SURF1 missense mutations promote a mild Leigh phenotype. Clin Genet (2009) 0.90
Gastrointestinal pathology in rhesus monkeys with experimental SIV infection. Pathobiology (1998) 0.90
Antibodies to HTLV-III in German blood donors. Lancet (1985) 0.90
Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J Gen Virol (1998) 0.90
Early phenotypic and functional alterations in lymphocytes from simian immunodeficiency virus infected macaques. Vet Immunol Immunopathol (1993) 0.90